Monitor upcoming preclinical data presentations and Phase I safety/dose escalation results, which could serve as catalysts. This trial expands HUTCHMED’s ATTC platform validation but is too early to impact near-term valuation.
Price Chart
Executive Summary
HUTCHMED has initiated a Phase I/IIa clinical trial for HMPL-A580, its second Antibody-Targeted Therapy Conjugate (ATTC), in patients with advanced solid tumors in both China and the US. The first patient was dosed on March 4, 2026, marking a key step in the development of this first-in-class therapy targeting the PAM pathway and EGFR signaling.
Key Facts
- HUTCHMED initiated a Phase I/IIa trial for HMPL-A580, its second ATTC candidate, on March 4, 2026.
- The trial is ongoing in the US and China and is first-in-human, evaluating safety, pharmacokinetics, and preliminary efficacy.
- HMPL-A580 combines a novel PI3K/PIKK inhibitor payload with an anti-EGFR antibody to target EGFR-expressing solid tumors.
- Preclinical data suggest synergistic activity between PAM pathway inhibition and EGFR blockade.
- Trial details are available at clinicaltrials.gov under NCT07396584.
Financial Impact
No immediate financial impact; early-stage trial with potential long-term value if clinical success is achieved
Risk Factors
- High risk typical of early-phase clinical development; safety or tolerability issues could halt development.
- Limited near-term commercial visibility; multi-year timeline to potential approval, if successful.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249083 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | 6-K | $14.11 $12.82 | ▼ −9.14% | ▼ −7.99% | $14.31 (+1.42%) |
Aug 31, 2026 4w ago | 6-K | $12.12 $13.88 | ▲ +14.52% | ▲ +14.66% | $14.31 (+18.07%) |
Aug 18, 2026 6w ago | 6-K | $12.64 $12.26 | ▼ −3.01% | ▼ −2.81% | $14.31 (+13.21%) |
Aug 17, 2026 6w ago | 6-K | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Aug 17, 2026 6w ago | Press Release | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Jul 30, 2026 9w ago | 6-K | $10.77 $11.83 | ▲ +9.84% | ▲ +6.22% | $14.31 (+32.87%) |
Jul 2, 2026 13w ago | 6-K | $11.44 $10.98 | ▼ −4.02% | ▼ −4.95% | $14.31 (+25.09%) |
Jun 30, 2026 13w ago | 6-K | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 30, 2026 13w ago | Press Release | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 29, 2026 13w ago | 6-K | $10.71 $11.65 | ▲ +8.78% | ▲ +7.39% | $14.31 (+33.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access